Atrial fibrillation is the most common arrhythmia worldwide. It is associated with a doubling in all-cause mortality. Despite this, disease-modifying therapies for the condition are lacking. Dr. Zachary Laksman from the Centre for Heart Lung Innovation, Dr. Filip Van Petegem from the Life Sciences Institute, UBC medical student Sina Safabakhsh, and the team review the evidence on the role of protein phosphorylation as a mechanism to target for the development of novel therapies.
